| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6589960 | FRESENIUS KABI USA | Hydromorphone and hydrocodone compositions and methods for their synthesis |
Nov, 2020
(3 years ago) | |
| US9731082 | FRESENIUS KABI USA | Drug container |
Apr, 2032
(7 years from now) | |
| US9248229 | FRESENIUS KABI USA | Packaging system for oxygen-sensitive drugs |
Mar, 2034
(9 years from now) | |
Dilaudid-Hp is owned by Fresenius Kabi Usa.
Dilaudid-Hp contains Hydromorphone Hydrochloride.
Dilaudid-Hp has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Dilaudid-Hp are:
- US6589960
Dilaudid-Hp was authorised for market use on 16 January, 2020.
Dilaudid-Hp is available in injectable;injection dosage forms.
The generics of Dilaudid-Hp are possible to be released after 12 March, 2034.
Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient
Market Authorisation Date: 16 January, 2020
Treatment: NA
Dosage: INJECTABLE;INJECTION
How can I launch a generic of DILAUDID-HP before it's drug patent expiration?
More Information on Dosage
DILAUDID-HP family patents
